Forward-looking statements Integra LifeSciences J.P. Morgan Healthcare Conference January 2026 Slide 2 A global medtech leader dedicated to restoring lives Demonstrated leadership in $9B global market Extensive portfolio of best-in-class products Executing strategic transformation Strengthening operational foundation Enabling growth and innovation 19% LTM adjusted EBTIDA margin 62.8% LTM adjusted gross margin $1.6B LTM reported revenue $89M LTM operating cash flow Slide 3 Financial metrics shown for the tra ...

Financial Performance - Q3 2025 revenue grew organically by 5% compared to Q3 2024[8, 9] - Adjusted EPS for Q3 2025 was $054, a 317% increase compared to $041 in Q3 2024[7, 10] - Adjusted EBITDA margin for Q3 2025 was 195%, a 330 bps increase compared to 162% in Q3 2024[10] - Q3 2025 operating cash flow was $409 million with a free cash flow conversion of 619%[11] Segment Performance - Codman Specialty Surgical (CSS) Q3 2025 revenue was $2926 million, with organic growth of 71% compared to Q3 2024[13] - Tissue Technologies Q3 2025 revenue was $1095 million, a 03% organic decrease compared to Q3 2024[17] Guidance and Outlook - Q4 2025 reported revenue is projected to be between $420 million and $440 million, with organic growth ranging from -59% to -14%[26] - Full year 2025 reported revenue is projected to be between $162 billion and $164 billion, with organic growth ranging from -16% to -04%[27, 28] - Full year 2025 adjusted EPS is projected to be between $219 and $224[28]